TNFRSF11A
Basic information
Region (hg38): 18:62325287-62391288
Previous symbols: [ "PDB2", "LOH18CR1" ]
Links
Phenotypes
GenCC
Source:
- osteosarcoma (Limited), mode of inheritance: AD
- autosomal recessive osteopetrosis 7 (Strong), mode of inheritance: AR
- dysosteosclerosis (Supportive), mode of inheritance: AR
- familial expansile osteolysis (Supportive), mode of inheritance: AD
- autosomal recessive osteopetrosis 7 (Supportive), mode of inheritance: AR
- familial expansile osteolysis (Moderate), mode of inheritance: AD
- autosomal recessive osteopetrosis 7 (Strong), mode of inheritance: AR
- dysosteosclerosis (Limited), mode of inheritance: AR
- Paget disease of bone 2, early-onset (Strong), mode of inheritance: AD
- autosomal recessive osteopetrosis 7 (Strong), mode of inheritance: AR
- Paget disease of bone 2, early-onset (Moderate), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Familial expansile osteolysis; Paget disease of bone 2, early-onset; Osteopetrosis, autosomal recessive 7 | AD/AR | Allergy/Immunology/Infectious; Endocrine; Musculoskeletal; Oncologic | In Osteopetrosis, autosomal recessive 7, individuals can present with hypocalcemic seizures, which are responsive to treatment; Antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; In Polyostotic osteolytic dysplasia, hereditary expansile, HSCT has been reported as effective, including when performed in late infancy; For Paget disease of bone, medical management (eg, inhibitors of osteoclastic bone resorption) can be beneficial - bisphosphonates are current first line of treatment, and awareness of the risk of related oncologic processes (eg, osteosarcoma) may be beneficial to allow early diagnosis and treatment | Allergy/Immunology/Infectious; Audiologic/Otolaryngologic; Craniofacial; Dental; Endocrine; Musculoskeletal; Oncologic | 3346299; 2530018; 9626117; 10615125; 11123042; 18606301; 18328984; 18672105; 19940926; 22271396 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (576 variants)
- Inborn_genetic_diseases (78 variants)
- Autosomal_recessive_osteopetrosis_7 (52 variants)
- Paget_disease_of_bone_2,_early-onset (41 variants)
- TNFRSF11A-related_disorder (20 variants)
- Familial_expansile_osteolysis (11 variants)
- not_specified (6 variants)
- Osteopetrosis (2 variants)
- Bone_Paget_disease (2 variants)
- Increased_bone_mineral_density (1 variants)
- Intellectual_disability (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TNFRSF11A gene is commonly pathogenic or not. These statistics are base on transcript: NM_000003839.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 143 | 155 | ||||
| missense | 322 | 18 | 350 | |||
| nonsense | 7 | |||||
| start loss | 1 | 2 | 3 | |||
| frameshift | 16 | |||||
| splice donor/acceptor (+/-2bp) | 4 | |||||
| Total | 17 | 11 | 340 | 161 | 6 |
Highest pathogenic variant AF is 0.000026529773
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| TNFRSF11A | protein_coding | protein_coding | ENST00000586569 | 10 | 65997 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.00877 | 0.991 | 125736 | 0 | 12 | 125748 | 0.0000477 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 1.29 | 279 | 347 | 0.805 | 0.0000209 | 3967 |
| Missense in Polyphen | 72 | 109.26 | 0.65895 | 1218 | ||
| Synonymous | 1.42 | 126 | 148 | 0.851 | 0.0000103 | 1219 |
| Loss of Function | 3.05 | 8 | 24.2 | 0.331 | 0.00000105 | 308 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000203 | 0.000203 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.0000360 | 0.0000352 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.0000327 | 0.0000327 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells. {ECO:0000269|PubMed:9878548}.;
- Disease
- DISEASE: Paget disease of bone 2, early-onset (PDB2) [MIM:602080]: A form of Paget disease, a disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone. {ECO:0000269|PubMed:10615125}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Osteopetrosis, autosomal recessive 7 (OPTB7) [MIM:612301]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia. {ECO:0000269|PubMed:18606301}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Prolactin signaling pathway - Homo sapiens (human);Rheumatoid arthritis - Homo sapiens (human);Osteoclast differentiation - Homo sapiens (human);NF-kappa B signaling pathway - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);Osteoclast Signaling;RANKL-RANK (Receptor activator of NFKB (ligand)) Signaling Pathway;TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway;TNFR2 non-canonical NF-kB pathway;Cytokine Signaling in Immune system;Immune System;bone remodeling;RANKL
(Consensus)
Intolerance Scores
- loftool
- 0.261
- rvis_EVS
- 0.67
- rvis_percentile_EVS
- 84.61
Haploinsufficiency Scores
- pHI
- 0.0838
- hipred
- Y
- hipred_score
- 0.597
- ghis
- 0.434
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.533
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tnfrsf11a
- Phenotype
- respiratory system phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); neoplasm; digestive/alimentary phenotype; limbs/digits/tail phenotype; immune system phenotype; skeleton phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype;
Gene ontology
- Biological process
- ossification;adaptive immune response;monocyte chemotaxis;signal transduction;cell-cell signaling;positive regulation of cell population proliferation;response to radiation;osteoclast differentiation;response to lipopolysaccharide;tumor necrosis factor-mediated signaling pathway;response to cytokine;response to tumor necrosis factor;positive regulation of JUN kinase activity;positive regulation of bone resorption;lymph node development;positive regulation of DNA-binding transcription factor activity;positive regulation of NF-kappaB transcription factor activity;circadian temperature homeostasis;mammary gland alveolus development;response to interleukin-1;positive regulation of fever generation by positive regulation of prostaglandin secretion;TNFSF11-mediated signaling pathway;positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling;multinuclear osteoclast differentiation
- Cellular component
- cytosol;plasma membrane;external side of plasma membrane;integral component of membrane
- Molecular function
- transmembrane signaling receptor activity;tumor necrosis factor-activated receptor activity;protein binding;cytokine binding;signaling receptor activity;metal ion binding